NCT05861128View on ClinicalTrials.gov

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

PHASE3RecruitingINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Jaktinib

Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks

Trial Locations (1)

200001

RECRUITING

Renji Hospital, Shanghai

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY